Advertisement
Advertisement

NEUP

NEUP logo

Neuphoria Therapeutics Inc. Common Stock

4.49
USD
Sponsored
+0.13
+2.98%
Jun 24, 15:59 UTC -4
Closed
exchange

After-Market

4.34

-0.15
-3.23%

NEUP Earnings Reports

Positive Surprise Ratio

NEUP beat 2 of 4 last estimates.

50%

Next Report

Date of Next Report
Sep 28, 2026
Estimate for Q4 26 (Revenue/ EPS)
--
/
-$0.57
Implied change from Q3 26 (Revenue/ EPS)
--
/
+533.33%
Implied change from Q4 25 (Revenue/ EPS)
-100.00%
/
-90.16%

Neuphoria Therapeutics Inc. Common Stock earnings per share and revenue

On May 15, 2026, NEUP reported earnings of -0.09 USD per share (EPS) for Q3 26, beating the estimate of -0.98 USD, resulting in a 90.90% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -7.07% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 5 analysts forecast an EPS of -0.57 USD, with revenue projected to reach -- USD, implying an increase of 533.33% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Vistagen Therapeutics, Inc. Common Stock
Report Date
Jun 15, 2026 For Q4 26
Estimate
-$0.34
Actual
-$0.37
Surprise
-7.75%
logo
enGene Therapeutics Inc. Common Stock
Report Date
Jun 15, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.43
Surprise
+10.32%
logo
Prenetics Global Limited Class A Ordinary Share
Report Date
Jun 10, 2026 For Q1 26
Estimate
-$1.10
Actual
-$1.61
Surprise
-45.36%
logo
Anixa Biosciences, Inc.
Report Date
Jun 10, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.07
Surprise
+21.61%
FAQ
For Q3 2026, Neuphoria Therapeutics Inc. Common Stock reported EPS of -$0.09, beating estimates by 90.9%, and revenue of $0.00, 0% as expectations.
The stock price moved down -7.07%, changed from $5.09 before the earnings release to $4.73 the day after.
The next earning report is scheduled for Sep 28, 2026.
Based on 5 analysts, Neuphoria Therapeutics Inc. Common Stock is expected to report EPS of -$0.57 and revenue of -- for Q4 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement